Sweden
- BioPorto Diagnostics A/S
- Grusbakken 8
- DK-2820 Gentofte
- Phone: (+45) 4529 0000
- Fax: (+45) 4529 0001
- Web: www.bioporto.com
- Web: www.ngal.com
- Mail: info@bioporto.com
VAT no.: DK-1864 5882
Terms and conditions
Returns
No returns can be accepted without prior written approval by the ordering channel (distributor or BioPorto Diagnostics). Only unopened merchandise that has been handled and stored as prescribed can be returned. No return of custom manufactured products will be authorized if the product meets the specifications agreed upon prior to shipment.
Alternate right
BioPorto Diagnostics reserves the right to change product specifications (e.g. buffer system) to maximize product quality.
Storage
Directions given on an individual datasheet or label are an integral part of these terms and conditions and must be strictly followed.
Freight
EXW (Copenhagen), charges is invoiced. BioPorto Diagnostics is not responsible for permits needed for customer clearances or other purposes.
Reservation of title
Unless otherwise marked, all products are for research use or further manufacture only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. Product codes: GAU*, MON* and DIA 011-01B, are not for further manufacture either.
CE-marked products comply with EU Directive 98/79/EC on in vitro diagnostic medical devices and are for in vitro diagnostic use in countries that recognize this legislation.
The NGAL Rapid ELISA Kit (KIT 037) is for diagnostic use in the European Union, Canada and India only.
The MBL Oligomer ELISA Kit (KIT 029) is for diagnostic use in the European Union, Canada and India only.
The Gc-globulin (Actin-free) ELISA Kit (KIT 034) is for diagnostic use in the European Union only.
All products remain the property of BioPorto Diagnostics A/S until full payment has been received.
The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics be responsible for loss of profits or indirect consequential losses resulting from use of its products.
